252 related articles for article (PubMed ID: 31802108)
1. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
2. Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
Ahn JS; Al-Habib A; Vos JA; Sohani AR; Barboza-Quintana O; Flores JP; Wen S; Rosado FG
Ann Clin Lab Sci; 2020 Mar; 50(2):213-218. PubMed ID: 32366559
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
4. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; Mego M; Mardiak J
BMC Cancer; 2018 Nov; 18(1):1062. PubMed ID: 30390643
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
[TBL] [Abstract][Full Text] [Related]
7. CD163
Kubota K; Moriyama M; Furukawa S; Rafiul HASM; Maruse Y; Jinno T; Tanaka A; Ohta M; Ishiguro N; Yamauchi M; Sakamoto M; Maehara T; Hayashida JN; Kawano S; Kiyoshima T; Nakamura S
Sci Rep; 2017 May; 7(1):1755. PubMed ID: 28496107
[TBL] [Abstract][Full Text] [Related]
8. Frequent PD-L1 expression in testicular germ cell tumors.
Fankhauser CD; Curioni-Fontecedro A; Allmann V; Beyer J; Tischler V; Sulser T; Moch H; Bode PK
Br J Cancer; 2015 Jul; 113(3):411-3. PubMed ID: 26171934
[TBL] [Abstract][Full Text] [Related]
9. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
12. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
[TBL] [Abstract][Full Text] [Related]
13. The role of the immunoescape in colorectal cancer liver metastasis.
Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
15. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
16. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
[TBL] [Abstract][Full Text] [Related]
20. PD-L1
Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
